![Kathy Dong](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Kathy Dong is currently the President & Chief Executive Officer at Electra Therapeutics, Inc. and also serves as a Director at Neuron23, Inc. Previously, she worked as the Chief Operating Officer at Star Therapeutics, Inc. Dr. Dong holds an MBA and a doctorate from the University of New Mexico School of Medicine.
| Bedrijven | Functie | Begin |
|---|---|---|
Neuron23, Inc.
 Neuron23, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company that focuses on developing precision medicines for genetically defined neurological and immunological diseases | Directeur/Bestuurslid | 14-06-2022 |
Electra Therapeutics, Inc.
 Electra Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures therapies for immunological diseases and cancer | Algemeen Directeur | 11-12-2023 |
| Bedrijven | Functie | Einde |
|---|---|---|
Star Therapeutics, Inc.
 Star Therapeutics, Inc. BiotechnologyHealth Technology Develops antibody therapies | Operationeel Directeur | - |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
| Bedrijven in privébezit | 4 |
|---|---|
University of New Mexico School of Medicine
 University of New Mexico School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Neuron23, Inc.
Neuron23, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company that focuses on developing precision medicines for genetically defined neurological and immunological diseases | Commercial Services |
Electra Therapeutics, Inc.
Electra Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures therapies for immunological diseases and cancer | Health Technology |
Star Therapeutics, Inc.
Star Therapeutics, Inc. BiotechnologyHealth Technology Develops antibody therapies | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau
Kies MarketScreener 
